[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"MBQ Pharma\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":45},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100521916",false,"NCT06075810","A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer","A Phase 1 Open-Label, First-in-Human Trial of Oral MBQ-167 as Single Agent in Participants With Advanced Breast Cancer","Key Inclusion Criteria:\n\n* The investigator will evaluate these and other criteria to determine whether a participant can be included in this study.\n* Histologically and\u002For cytologically confirmed advanced breast cancer which has progressed after treatment with approved therapies or for which there are no standard therapies available.\n* Participants with known brain metastases may be eligible if specific conditions are met.\n* Life expectancy ≥6 months, in the opinion of the investigator, after starting MBQ-167.\n* Are able to swallow capsules twice daily with a meal.\n\nKey Exclusion Criteria:\n\n* The investigator will evaluate these and other criteria to determine whether a participant should be excluded from this study.\n* Inability to take oral medication, or malabsorption syndrome or any other uncontrolled gastrointestinal condition (e.g., nausea, diarrhea, or vomiting) that might impair the bioavailability of MBQ-167.\n* Females who are pregnant or breastfeeding.\n* Participants who have received any anticancer treatment within 4 weeks or any investigational agent within 28 days prior to the first dose of trial drug or who have not recovered from any acute toxicity greater than Grade 0 or 1 related to previous anticancer treatment.\n* Participants who have received any anticancer treatment within 4 weeks or any investigational agent within 28 days prior to the first dose of trial drug or who have not recovered from any acute toxicity greater than Grade 0 or 1 related to previous anticancer treatment.\n* Active malignancies other than advanced breast cancer will be excluded from the study.","ALL","21 Years",{"count":18,"type":19},48,"ESTIMATED","INTERVENTIONAL",[22],"PHASE1","A Phase 1, open-label, dose-escalation clinical trial of MBQ-167 in participants with advanced Breast Cancer for whom Standard of Care (SOC) has failed or has proven intolerable.",[25,26,27],"Breast Cancer","Breast Neoplasm","Breast Cancer Stage IV",[29,30,31],"Advanced Breast Cancer","Metastatic Breast Cancer","Recurrent Breast Cancer","RECRUITING","2024-12-09",{"date":35,"type":36},"2024-12-12","ACTUAL",{"date":38,"type":36},"2023-11-09",{"date":40,"type":19},"2025-10-31",{"name":42,"class":43},"MBQ Pharma","INDUSTRY",4,""]